89 related articles for article (PubMed ID: 24384472)
21. Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression--transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway.
Choi HJ; Chung TW; Kang SK; Lee YC; Ko JH; Kim JG; Kim CH
Glycobiology; 2006 Jul; 16(7):573-83. PubMed ID: 16574813
[TBL] [Abstract][Full Text] [Related]
22. Highly pathogenic Alzheimer's disease presenilin 1 P117R mutation causes a specific increase in p53 and p21 protein levels and cell cycle dysregulation in human lymphocytes.
Bialopiotrowicz E; Szybinska A; Kuzniewska B; Buizza L; Uberti D; Kuznicki J; Wojda U
J Alzheimers Dis; 2012; 32(2):397-415. PubMed ID: 22810102
[TBL] [Abstract][Full Text] [Related]
23. Clostridium difficile toxin A-induced colonocyte apoptosis involves p53-dependent p21(WAF1/CIP1) induction via p38 mitogen-activated protein kinase.
Kim H; Kokkotou E; Na X; Rhee SH; Moyer MP; Pothoulakis C; Lamont JT
Gastroenterology; 2005 Dec; 129(6):1875-88. PubMed ID: 16344056
[TBL] [Abstract][Full Text] [Related]
24. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
25. Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression.
Hiyama H; Iavarone A; LaBaer J; Reeves SA
Oncogene; 1997 May; 14(21):2533-42. PubMed ID: 9191053
[TBL] [Abstract][Full Text] [Related]
26. MiR-17/106b seed family regulates p21 in Hodgkin's lymphoma.
Gibcus JH; Kroesen BJ; Koster R; Halsema N; de Jong D; de Jong S; Poppema S; Kluiver J; Diepstra A; van den Berg A
J Pathol; 2011 Dec; 225(4):609-17. PubMed ID: 21953646
[TBL] [Abstract][Full Text] [Related]
27. A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function.
Kokontis JM; Wagner AJ; O'Leary M; Liao S; Hay N
Oncogene; 2001 Feb; 20(6):659-68. PubMed ID: 11313999
[TBL] [Abstract][Full Text] [Related]
28. The proliferation-associated early response gene p22/PRG1 is a novel p53 target gene.
Schäfer H; Trauzold A; Sebens T; Deppert W; Fölsch UR; Schmidt WE
Oncogene; 1998 May; 16(19):2479-87. PubMed ID: 9627114
[TBL] [Abstract][Full Text] [Related]
29. Transcriptional up-regulation of Sox9 by NF-κB in endometrial carcinoma cells, modulating cell proliferation through alteration in the p14(ARF)/p53/p21(WAF1) pathway.
Saegusa M; Hashimura M; Suzuki E; Yoshida T; Kuwata T
Am J Pathol; 2012 Aug; 181(2):684-92. PubMed ID: 22698986
[TBL] [Abstract][Full Text] [Related]
30. The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53-independent mechanisms.
Kovacevic Z; Sivagurunathan S; Mangs H; Chikhani S; Zhang D; Richardson DR
Carcinogenesis; 2011 May; 32(5):732-40. PubMed ID: 21398495
[TBL] [Abstract][Full Text] [Related]
31. In vitro transcriptional activation of p21 promoter by p53.
Kim TK
Biochem Biophys Res Commun; 1997 May; 234(2):300-2. PubMed ID: 9177263
[TBL] [Abstract][Full Text] [Related]
32. Induction of apoptosis by the p53-273L (Arg --> Leu) mutant in HSC3 cells without transactivation of p21Waf1/Cip1/Sdi1 and bax.
Kaneuchi M; Yamashita T; Shindoh M; Segawa K; Takahashi S; Furuta I; Fujimoto S; Fujinaga K
Mol Carcinog; 1999 Sep; 26(1):44-52. PubMed ID: 10487521
[TBL] [Abstract][Full Text] [Related]
33. Nature of G1/S cell cycle checkpoint defect in ataxia-telangiectasia.
Khanna KK; Beamish H; Yan J; Hobson K; Williams R; Dunn I; Lavin MF
Oncogene; 1995 Aug; 11(4):609-18. PubMed ID: 7651723
[TBL] [Abstract][Full Text] [Related]
34. Expression of hepaCAM is downregulated in cancers and induces senescence-like growth arrest via a p53/p21-dependent pathway in human breast cancer cells.
Moh MC; Zhang T; Lee LH; Shen S
Carcinogenesis; 2008 Dec; 29(12):2298-305. PubMed ID: 18845560
[TBL] [Abstract][Full Text] [Related]
35. Lysines in the tetramerization domain of p53 selectively modulate G1 arrest.
Beckerman R; Yoh K; Mattia-Sansobrino M; Zupnick A; Laptenko O; Karni-Schmidt O; Ahn J; Byeon IJ; Keezer S; Prives C
Cell Cycle; 2016 Jun; 15(11):1425-38. PubMed ID: 27210019
[TBL] [Abstract][Full Text] [Related]
36. C-terminal region of human p53 attenuates buffalo p53 N-terminal-specific transactivation of p21 promoter by modulating tetramerization of the protein.
Singh M; Mukhopadhyay T
Mol Cell Biochem; 2018 Jun; 443(1-2):101-110. PubMed ID: 29147811
[TBL] [Abstract][Full Text] [Related]
37. HCV NS5A abrogates p53 protein function by interfering with p53-DNA binding.
Gong GZ; Jiang YF; He Y; Lai LY; Zhu YH; Su XS
World J Gastroenterol; 2004 Aug; 10(15):2223-7. PubMed ID: 15259070
[TBL] [Abstract][Full Text] [Related]
38. Interaction between transactivation domain of p53 and middle part of TBP-like protein (TLP) is involved in TLP-stimulated and p53-activated transcription from the p21 upstream promoter.
Maeda R; Suzuki H; Tanaka Y; Tamura TA
PLoS One; 2014; 9(3):e90190. PubMed ID: 24594805
[TBL] [Abstract][Full Text] [Related]
39. Transactivation by low and high levels of human p53 reveals new physical rules of engagement and novel super-transactivation sequences.
Menendez D; Resnick MA; Haran T
Cell Cycle; 2012 Dec; 11(23):4287-8. PubMed ID: 23095671
[No Abstract] [Full Text] [Related]
40. Characterization of the p53 cistrome--DNA binding cooperativity dissects p53's tumor suppressor functions.
Schlereth K; Heyl C; Krampitz AM; Mernberger M; Finkernagel F; Scharfe M; Jarek M; Leich E; Rosenwald A; Stiewe T
PLoS Genet; 2013; 9(8):e1003726. PubMed ID: 23966881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
